![Meike Heurich-Sevcenco](https://profiles-cardiff.imgix.net/attachments/10360?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Meike Heurich-Sevcenco
(hi/ei)
- Ar gael fel goruchwyliwr ôl-raddedig
Timau a rolau for Meike Heurich-Sevcenco
Uwch Ddarlithydd
Trosolwyg
Mae Dr Meike Heurich-Sevcenco yn Uwch Ddarlithydd yn yr Ysgol Fferylliaeth a Gwyddorau Fferyllol ym Mhrifysgol Caerdydd.
Mae ei hymchwil yn canolbwyntio ar imiwnoleg foleciwlaidd a sut mae proteinau'r imiwnedd a gludir gan y gwaed a'r system geulo yn rhyngweithio ar lefel foleciwlaidd a chellog a sut mae eu camreoleiddio yn cyfrannu at glefyd. Pwyslais mawr ar ei gwaith mewn imiwnoseiciatreg yw deall newidiadau imiwnedd mewn seicosis a sgitsoffrenia, gyda'r nod o nodi biofarcwyr sy'n seiliedig ar waed, a thargedau therapiwtig newydd.
Trwy broffilio manwl o lefelau protein, eu cynhyrchion actifadu, a dynameg llwybr mewn plasma dynol, mae ei grŵp yn mynd i'r afael â chwestiynau clinigol perthnasol ynghylch biofarcwyr ar gyfer haenu clefydau, rhagfynegi ymateb triniaeth, a dilysu targed cyffuriau.
Mae Meike yn gweithio'n agos gyda'r grŵp Bassetto (Dr Marcella Bassetto - Pobl - Prifysgol Caerdydd)
Ein tîm ymchwil:
Dr Ruth Lewis - Pobl - Prifysgol Caerdydd
Cyhoeddiad
2026
- Howes, O. D. , Arumuham, A. and Heurich-Sevcenco, M. 2026. Targets for disease modification in schizophrenia: New findings add to evidence for the involvement of the immune complement system [Commentray]. Proceedings of the National Academy of Sciences 123 (27) e2613745123. (10.1073/pnas.2613745123)
2024
- Heurich, M. , Föcking, M. and Cotter, D. 2024. Complement C4, C4A and C4a – what they do and how they differ. Brain, Behavior, & Immunity - Health 39 100809. (10.1016/j.bbih.2024.100809)
- Byrne, J. F. et al., 2024. Plasma complement and coagulation proteins as prognostic factors of negative symptoms: An analysis of the NAPLS 2 and 3 studies. Brain, Behavior, and Immunity 119 , pp.188-196. (10.1016/j.bbi.2024.03.049)
- Kodosaki, E. et al., 2024. Sample processing time but not storage time affects complement activation markers C4a, C4d, C3a, C3d, Bb, C5a, and sC5b-9 levels in EDTA-plasma of individuals at clinical high-risk for psychosis. Biomarkers in Neuropsychiatry 10 100097. (10.1016/j.bionps.2024.100097)
- Byrne, J. F. et al., 2024. Proteomic biomarkers for the prediction of transition to psychosis in individuals at clinical high risk: A multi-cohort model development study. Schizophrenia Bulletin 50 (3), pp.579-588. (10.1093/schbul/sbad184)
- Healy, C. et al., 2024. Differential expression of haptoglobin in individuals at clinical high risk of psychosis and its association with global functioning and clinical symptoms. Brain, Behavior, and Immunity 117 , pp.175-180. (10.1016/j.bbi.2023.12.018)
2023
- Heurich, M. and McCluskey, G. 2023. Complement and coagulation crosstalk - Factor H in the spotlight. Immunobiology 228 (6) 152707. (10.1016/j.imbio.2023.152707)
- Cropley, V. et al., 2023. Complement proteins are elevated in blood serum but not CSF in clinical high-risk and antipsychotic-naïve first-episode psychosis. Brain, Behavior, and Immunity 113 , pp.136-144. (10.1016/j.bbi.2023.07.004)
- Susai, S. R. et al., 2023. Association of complement and coagulation pathway proteins with treatment response in first-episode psychosis: a longitudinal analysis of the OPTiMiSE clinical trial. Schizophrenia Bulletin: The Journal of Psychoses and Related Disorders 49 (4), pp.893-902. (10.1093/schbul/sbac201)
2022
- Susai, S. R. et al., 2022. Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis. Translational Psychiatry 12 454. (10.1038/s41398-022-02217-0)
- Heurich, M. et al. 2022. Dysregulation of complement and coagulation pathways: emerging mechanisms in the development of psychosis. Molecular Psychiatry 27 , pp.127-140. (10.1038/s41380-021-01197-9)
2021
- Baker, A. T. et al., 2021. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Science Advances 7 (49) eabl8213. (10.1126/sciadv.abl8213)
- Pathare, N. et al. 2021. Plasma IgM levels differentiate between survivors and non-survivors of culture-positive and culture-negative sepsis and SIRS: a pilot study. Journal of Clinical Medicine 10 (22) 5391. (10.3390/jcm10225391)
- Howes, O. , Cummings, C. and Heurich, M. 2021. Translation from genes to mechanism in schizophrenia: are immune-synaptic interactions the missing link?. Biological Psychiatry 90 (9), pp.593-595. (10.1016/j.biopsych.2021.08.014)
- Flude, B. M. et al., 2021. Targeting the complement serine protease MASP-2 as a therapeutic strategy for coronavirus infections. Viruses 13 (2) 312. (10.3390/v13020312)
- Mongan, D. et al., 2021. Development of proteomic prediction models for transition to psychotic disorder in the clinical high-risk state and psychotic experiences in adolescence. JAMA Psychiatry 78 (1), pp.77-90. (10.1001/jamapsychiatry.2020.2459)
2019
- Madrid-Gambin, F. et al., 2019. Integrated lipidomics and proteomics point to early blood-based changes in childhood preceding later development of psychotic experiences: evidence from the Avon Longitudinal Study of Parents and Children. Biological Psychiatry 86 (1), pp.25-34. (10.1016/j.biopsych.2019.01.018)
- Föcking, M. et al., 2019. Complement pathway changes at age 12 are associated with psychotic experiences at age 18 in a longitudinal population-based study: evidence for a role of stress. Molecular Psychiatry 26 , pp.524-533. (10.1038/s41380-018-0306-z)
2016
- Heurich-Sevcenco, M. et al. 2016. Thrombomodulin enhances complement regulation through strong affinity interactions with factor H and C3b-Factor H complex. Thrombosis Research 145 , pp.84-92. (10.1016/j.thromres.2016.07.017)
2015
- Martínez-Barricarte, R. et al., 2015. The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome. Molecular Immunology 66 (2), pp.263-273. (10.1016/j.molimm.2015.03.248)
- Szakmany, T. and Heurich-Sevcenco, M. 2015. Immunomodulation in sepsis - why blunting the response doesn't work?. Journal of Infection 71 (2), pp.147-149. (10.1016/j.jinf.2015.04.019)
2014
- Ruseva, M. and Heurich-Sevcenco, M. 2014. Purification and characterization of human and mouse complement C3. In: Gadjeva, M. ed. The Complement System: Methods and Protocols. Vol. 1100, Methods in Molecular Biology Humana Press. , pp.75-91. (10.1007/978-1-62703-724-2_6)
2013
- Heurich, M. , Altintas, Z. and Tothill, I. 2013. Computational Design of Peptide Ligands for Ochratoxin A. Toxins 5 (6), pp.1202-1218. (10.3390/toxins5061202)
2012
- Harris, C. L. et al. 2012. The complotype: dictating risk for inflammation and infection. Trends in Immunology 33 (10), pp.513-521. (10.1016/j.it.2012.06.001)
2011
- Heurich, M. et al. 2011. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proceedings of the National Academy of Sciences of the United States of America 108 (21), pp.8761-8766. (10.1073/pnas.1019338108)
2010
- Martínez-Barricarte, R. et al., 2010. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. Journal of Clinical Investigation 120 (10), pp.3702-3712. (10.1172/JCI43343)
Articles
- Howes, O. D. , Arumuham, A. and Heurich-Sevcenco, M. 2026. Targets for disease modification in schizophrenia: New findings add to evidence for the involvement of the immune complement system [Commentray]. Proceedings of the National Academy of Sciences 123 (27) e2613745123. (10.1073/pnas.2613745123)
- Heurich, M. , Föcking, M. and Cotter, D. 2024. Complement C4, C4A and C4a – what they do and how they differ. Brain, Behavior, & Immunity - Health 39 100809. (10.1016/j.bbih.2024.100809)
- Byrne, J. F. et al., 2024. Plasma complement and coagulation proteins as prognostic factors of negative symptoms: An analysis of the NAPLS 2 and 3 studies. Brain, Behavior, and Immunity 119 , pp.188-196. (10.1016/j.bbi.2024.03.049)
- Kodosaki, E. et al., 2024. Sample processing time but not storage time affects complement activation markers C4a, C4d, C3a, C3d, Bb, C5a, and sC5b-9 levels in EDTA-plasma of individuals at clinical high-risk for psychosis. Biomarkers in Neuropsychiatry 10 100097. (10.1016/j.bionps.2024.100097)
- Byrne, J. F. et al., 2024. Proteomic biomarkers for the prediction of transition to psychosis in individuals at clinical high risk: A multi-cohort model development study. Schizophrenia Bulletin 50 (3), pp.579-588. (10.1093/schbul/sbad184)
- Healy, C. et al., 2024. Differential expression of haptoglobin in individuals at clinical high risk of psychosis and its association with global functioning and clinical symptoms. Brain, Behavior, and Immunity 117 , pp.175-180. (10.1016/j.bbi.2023.12.018)
- Heurich, M. and McCluskey, G. 2023. Complement and coagulation crosstalk - Factor H in the spotlight. Immunobiology 228 (6) 152707. (10.1016/j.imbio.2023.152707)
- Cropley, V. et al., 2023. Complement proteins are elevated in blood serum but not CSF in clinical high-risk and antipsychotic-naïve first-episode psychosis. Brain, Behavior, and Immunity 113 , pp.136-144. (10.1016/j.bbi.2023.07.004)
- Susai, S. R. et al., 2023. Association of complement and coagulation pathway proteins with treatment response in first-episode psychosis: a longitudinal analysis of the OPTiMiSE clinical trial. Schizophrenia Bulletin: The Journal of Psychoses and Related Disorders 49 (4), pp.893-902. (10.1093/schbul/sbac201)
- Susai, S. R. et al., 2022. Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis. Translational Psychiatry 12 454. (10.1038/s41398-022-02217-0)
- Heurich, M. et al. 2022. Dysregulation of complement and coagulation pathways: emerging mechanisms in the development of psychosis. Molecular Psychiatry 27 , pp.127-140. (10.1038/s41380-021-01197-9)
- Baker, A. T. et al., 2021. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Science Advances 7 (49) eabl8213. (10.1126/sciadv.abl8213)
- Pathare, N. et al. 2021. Plasma IgM levels differentiate between survivors and non-survivors of culture-positive and culture-negative sepsis and SIRS: a pilot study. Journal of Clinical Medicine 10 (22) 5391. (10.3390/jcm10225391)
- Howes, O. , Cummings, C. and Heurich, M. 2021. Translation from genes to mechanism in schizophrenia: are immune-synaptic interactions the missing link?. Biological Psychiatry 90 (9), pp.593-595. (10.1016/j.biopsych.2021.08.014)
- Flude, B. M. et al., 2021. Targeting the complement serine protease MASP-2 as a therapeutic strategy for coronavirus infections. Viruses 13 (2) 312. (10.3390/v13020312)
- Mongan, D. et al., 2021. Development of proteomic prediction models for transition to psychotic disorder in the clinical high-risk state and psychotic experiences in adolescence. JAMA Psychiatry 78 (1), pp.77-90. (10.1001/jamapsychiatry.2020.2459)
- Madrid-Gambin, F. et al., 2019. Integrated lipidomics and proteomics point to early blood-based changes in childhood preceding later development of psychotic experiences: evidence from the Avon Longitudinal Study of Parents and Children. Biological Psychiatry 86 (1), pp.25-34. (10.1016/j.biopsych.2019.01.018)
- Föcking, M. et al., 2019. Complement pathway changes at age 12 are associated with psychotic experiences at age 18 in a longitudinal population-based study: evidence for a role of stress. Molecular Psychiatry 26 , pp.524-533. (10.1038/s41380-018-0306-z)
- Heurich-Sevcenco, M. et al. 2016. Thrombomodulin enhances complement regulation through strong affinity interactions with factor H and C3b-Factor H complex. Thrombosis Research 145 , pp.84-92. (10.1016/j.thromres.2016.07.017)
- Martínez-Barricarte, R. et al., 2015. The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome. Molecular Immunology 66 (2), pp.263-273. (10.1016/j.molimm.2015.03.248)
- Szakmany, T. and Heurich-Sevcenco, M. 2015. Immunomodulation in sepsis - why blunting the response doesn't work?. Journal of Infection 71 (2), pp.147-149. (10.1016/j.jinf.2015.04.019)
- Heurich, M. , Altintas, Z. and Tothill, I. 2013. Computational Design of Peptide Ligands for Ochratoxin A. Toxins 5 (6), pp.1202-1218. (10.3390/toxins5061202)
- Harris, C. L. et al. 2012. The complotype: dictating risk for inflammation and infection. Trends in Immunology 33 (10), pp.513-521. (10.1016/j.it.2012.06.001)
- Heurich, M. et al. 2011. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proceedings of the National Academy of Sciences of the United States of America 108 (21), pp.8761-8766. (10.1073/pnas.1019338108)
- Martínez-Barricarte, R. et al., 2010. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. Journal of Clinical Investigation 120 (10), pp.3702-3712. (10.1172/JCI43343)
Book sections
- Ruseva, M. and Heurich-Sevcenco, M. 2014. Purification and characterization of human and mouse complement C3. In: Gadjeva, M. ed. The Complement System: Methods and Protocols. Vol. 1100, Methods in Molecular Biology Humana Press. , pp.75-91. (10.1007/978-1-62703-724-2_6)
Ymchwil
Mae Dr Meike Heurich-Sevcenco yn Uwch Ddarlithydd yn yr Ysgol Fferylliaeth a Gwyddorau Fferyllol ym Mhrifysgol Caerdydd. Mae hi'n arwain Ymchwil mewn Imiwnoleg Moleciwlaidd ac Imiwnoseiciatreg.
Mae imiwnoseiciatreg yn faes rhyngddisgyblaethol sy'n ymchwilio i'r rhyngweithiadau rhwng y system imiwnedd ac anhwylderau seiciatrig. Mae'n archwilio sut y gall dysregulation imiwnedd a llid ddylanwadu ar swyddogaeth yr ymennydd a chyfrannu at pathogenesis, symptomau, a dilyniant salwch meddwl.
Mae meysydd ymchwil craidd yn cynnwys:
System Imiwnedd-Gyflenwad a Seicosis: Mae hi'n ymchwilio i sut mae proteinau gwaed sy'n ymwneud ag imiwnedd cynhenid yn rhyngweithio â'r system geulo ac yn cyfrannu at anhwylderau seicotig.
Prosesau Niwrollid: Nodi actifadu aberrant cydrannau neu gelloedd imiwnedd yn yr ymylon a'r ymennydd sy'n effeithio ar blastigrwydd synaptig.
Datblygu Biofarcwyr: Nodi marcwyr llidiol ymylol (e.e. marcwyr actifadu cyflenwad) i haenu cleifion a phersonoli strategaethau triniaeth.
Ymchwil Mecanistaidd: Defnyddio technegau moleciwlaidd a chellog i ddilysu proteinau imiwnedd fel targedau therapiwtig mewn sgitsoffrenia.
Therapiwteg Niwroseiciatrig: Archwilio sut y gall imiwnomodwleiddio ddylanwadu ar blastigrwydd synaptig ac o bosibl cynyddu triniaeth seiciatrig safonol, yn enwedig mewn is-grwpiau â phroffiliau llidiol uchel.
Cydweithredu Rhyngddisgyblaethol: Gweithio gyda thimau seiciatreg, niwrobioleg a chemeg feddyginiaethol i gyfieithu ymchwil sy'n canolbwyntio ar imiwnedd i ymyriadau clinigol posibl.
Mae ein hymchwil yn cael ei ariannu gan:
Ymddiriedolaeth Wellcome 2026-2028
2023-2024 Sefydliad BMA Grant Margaret Temple
Ymddiriedolaeth Wellcome 2021-2023
Arbenigedd technegol:
- Biocemeg protein (mynegiannu, puro, nodweddu)
- Ategu bioleg a signalau imiwnedd
- Technegau imiwnoleg moleciwlaidd
- Immunoassays (ELISA, Western blotting)
- Diwylliant celloedd a modelau clefyd in vitro
- Dadansoddiad rhyngweithio protein-protein (e.e. Biacore)
- Dulliau therapiwteg trosiadol ac arbrofol
E-bostiwch [email protected] am ragor o wybodaeth.
Ein Newyddion
Hysbysebu ar hyn o bryd am swydd PhD (Dyddiad cau: Dydd Mercher 21 Hydref 2026)
Tuag at Seiciatreg Fanwl: Canfod ac Ymyrryd yn Gynnar mewn Sgitsoffrenia - GW4 BioMed MRC DTP
Addysgu
Rwy'n darparu arweinyddiaeth strategol a pharhaus mewn addysgu ar draws rhaglenni israddedig ac ôl-raddedig mewn fferylliaeth a gwyddorau biofeddygol, gan ddarparu addysg dan arweiniad ymchwil ar draws bioleg celloedd, imiwnoleg, clefydau clinigol, a dulliau ymchwil.
Ar y rhaglen MPharm rwy'n cyfrannu at bob cam o'r rhaglen. Rwy'n Arweinydd Modiwl ar gyfer y modiwl Strwythur a Swyddogaeth Celloedd ac yn cyfrannu addysgu ar sut mae trefniadaeth gellog yn sail i iechyd a chlefydau. Rwy'n Arweinydd Uned ar gyfer Imiwnoleg Sylfaenol o fewn addysgu ar y modiwl system corff dynol, gan gyflwyno myfyrwyr i ymatebion imiwnedd cynhenid ac addasol a'u perthnasedd ffisiolegol. Rwyf hefyd yn arwain yr Uned Imiwnoleg Glinigol, gan integreiddio mecanweithiau imiwnedd â pathogenesis a thrin clefydau, ac yn darlithio mewn rhiwmatoleg, gan ganolbwyntio ar reoli clefydau a dulliau therapiwtig.
Rwy'n goruchwylio prosiectau ymchwil MPharm blwyddyn olaf, gan gefnogi myfyrwyr trwy gynllunio prosiectau, dylunio arbrofol, dadansoddi data, ac ysgrifennu adroddiadau. Mae'r goruchwyliaeth hon yn datblygu annibyniaeth, meddwl beirniadol a llythrennedd ymchwil myfyrwyr, ac yn eu paratoi ar gyfer ymarfer proffesiynol neu astudiaeth ôl-raddedig.
Ar lefel ôl-raddedig, rwy'n cyfrannu at yr MSc mewn Bioleg Canser, gan ddarparu addysgu ymarferol mewn dulliau ymchwil. Mae'r addysgu hwn yn canolbwyntio ar drylwyredd arbrofol, dehongli data, a sgiliau labordy trosglwyddadwy.
Rwy'n cymryd rhan weithredol mewn dylunio, marcio ac adborth asesu, gan sicrhau bod asesiadau yn cyd-fynd â deilliannau dysgu ac yn hyrwyddo dysgu.
Mae fy addysgu wedi'i lywio'n agos gan fy arbenigedd ymchwil mewn imiwnoleg, llid a chlefyd imiwnedd, gan sicrhau bod myfyrwyr yn ymgysylltu â gwyddoniaeth biofeddygol gyfoes a throsiannol.
Bywgraffiad
Mae Dr Meike Heurich-Sevcenco yn Uwch Ddarlithydd yn yr Ysgol Fferylliaeth a Gwyddorau Fferyllol ym Mhrifysgol Caerdydd. Mae hi'n arwain ymchwil mewn imiwnoleg foleciwlaidd ac imiwnoseiciatreg, gan adeiladu ar arbenigedd helaeth mewn bioleg ategol a signalau imiwnedd mewn iechyd a chlefydau. Ar ôl cwblhau PhD mewn Ymchwil Biocemegol a Bioffisegol, roedd ganddi gyfres o swyddi ymchwil a chymrodoriaeth yng Nghaerdydd, gan gynnwys Cymrodoriaeth Ymchwil Datblygu Gyrfa. Fe'i penodwyd yn Ddarlithydd yn 2017 a'i dyrchafu'n Uwch Ddarlithydd yn 2022. Ochr yn ochr â'i hymchwil, mae'n cyfrannu at addysgu israddedig ac ôl-raddedig a goruchwylio ymchwil.
Penodiadau Academaidd
Uwch Ddarlithydd (Addysgu ac Ymchwil)
Ymchwil mewn Imiwnoleg Moleciwlaidd ac Imiwnoseiciatreg
Coleg y Gwyddorau Biofeddygol a Bywyd, Ysgol Fferylliaeth a Gwyddorau Fferyllol,
Prifysgol Caerdydd, DU
08/2022 – presennol
Darlithydd (Addysgu ac Ymchwil)
Coleg y Gwyddorau Biofeddygol a Bywyd, Ysgol Fferylliaeth a Gwyddorau Fferyllol,
Prifysgol Caerdydd, DU
01/2017 – 07/2022
Uwch Ymchwilydd Ôl-ddoethurol
Ymchwil mewn Imiwnoleg Moleciwlaidd a Firoleg
Coleg y Gwyddorau Biofeddygol a Bywyd, Ysgol Meddygaeth,
Sefydliad Heintiau ac Imiwnedd,
Prifysgol Caerdydd, DU
06/2016 – 12/2016
Cymrawd Ymchwil Datblygu Gyrfa
Ymchwil mewn imiwnoleg foleciwlaidd a haemostasis
Coleg y Gwyddorau Biofeddygol a Bywyd, Ysgol Meddygaeth,
Sefydliad Heintiau ac Imiwnedd,
Prifysgol Caerdydd, DU
03/2012 – 06/2016
Cydymaith Ymchwil Ôl-ddoethurol
Ymchwil mewn Bioleg Ategol
Sefydliad Meddygaeth Seicolegol a Niwrowyddorau Clinigol a
Sefydliad Heintiau ac Imiwnedd, Ysgol Feddygaeth,
Prifysgol Caerdydd, DU
09/2011 – 02/2012
Cydymaith Ymchwil Ôl-ddoethurol
Ymchwil mewn Bioleg Ategol
Adran Heintiau, Imiwnedd a Biocemeg, Ysgol Feddygaeth,
Prifysgol Caerdydd, DU
09/2008 – 08/2011
Cynorthwy-ydd Ymchwil
Ymchwil mewn Bioleg Ategol
Adran Biocemeg Feddygol, Ysgol Meddygaeth,
Prifysgol Caerdydd, DU
04/2007 – 07/2008
Addysg
PhD mewn Ymchwil Biocemegol a Bioffisegol
Canolfan Biotechnoleg Cranfield, Prifysgol Cranfield, DU
04/2004 – 04/2008
Gradd mewn Biocemeg
Prifysgol Potsdam, yr Almaen
10/1997 – 09/2003
News articles
Contact Details
+44 29208 76657
Adeilad Redwood , Ystafell 2.57B, Rhodfa'r Brenin Edward VII, Caerdydd, CF10 3NB
